Rebekka Spellerberg
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
TGF-β1-based restoration of sodium iodide symporter expression in radioiodine-refractory differentiated thyroid cancer via engineered MSCs.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 21, 2025
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice.
Journal: Molecular therapy oncolytics
Published: February 10, 2023
Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma.
Journal: Molecular therapy oncolytics
Published: May 24, 2022
Mesenchymal Stem Cell-mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 04, 2022
The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy.
Journal: EJNMMI research
Published: October 07, 2021
Selective sodium iodide symporter (NIS) genetherapy of glioblastoma mediatedby EGFR-targeted lipopolyplexes.
Journal: Molecular therapy oncolytics
Published: May 29, 2021
Integrin αvβ3-Mediated Effects of Thyroid Hormones on Mesenchymal Stem Cells in Tumor Angiogenesis.
Journal: Thyroid : official journal of the American Thyroid Association
Published: December 10, 2019
Radiation-Induced Amplification of TGFB1-Induced Mesenchymal Stem Cell-Mediated Sodium Iodide Symporter (NIS) Gene 131I Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 14, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026